Loading clinical trials...
Loading clinical trials...
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II, Multicenter, Single-Arm Clinical Trial
Conditions
Interventions
Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
Locations
3
China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Start Date
August 1, 2025
Primary Completion Date
August 31, 2026
Completion Date
June 30, 2028
Last Updated
July 18, 2025
NCT07459296
NCT07340515
NCT06982300
NCT07085988
NCT07072143
NCT06870435
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions